QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors

Inclusion Criteria

• •Male and female subjects ≥ 16 years of age with a diagnosis of EFT or DSRCT who have relapsed or progressed after at least one prior chemotherapeutic regimen will be eligible for this study.
• •Before any study-specific procedure, the appropriate written informed consent must be obtained.
• •Disease Related Subjects with pathological or histological diagnosis of Ewing's Family Tumor or Desmoplastic Small Round Cell Tumor.
• •Measurable disease as defined by RECIST.
• •Documented failure of at least one prior chemotherapy regimen for their disease.
• •Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2.
• •Demographic
• •Males or females ≥ 16 years old.
• •Signed written informed consent.
• •Able to comply with visits and procedures.
• •Laboratory
• •Willing to provide existing and/or newly acquired tumor samples.
• •Diabetic Subjects (Type 1 or 2) must have HgbA1c \< 8.0% and fasting blood glucose level \< 160 mg/dL.
• •General
• •Must be willing and able to use birth control (double barrier protection or abstinence) during and for 6 months after the study
• •Prior exposure to another anti-IGF-1R therapy will only be allowed for a limited number of additional subjects (up to 10) in an exploratory cohort